System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Benjamin Besse is an expert in Oncology at Institut Gustave Roussy (France). As of October 2026, ScienceLeadR ranks Benjamin Besse in the top 1% of experts worldwide for Lung Neoplasms, Thoracic Neoplasms and Bronchial Neoplasms. Benjamin Besse has authored 1,398 publications, the most recent in 2026, and is an investigator in 62 clinical trials, 12 of them ongoing. SLR score: 7,208 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Benjamin Besse Institut Gustave Roussy France
7 208 ScienceLeadR Reputation 7208

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pulmonology - Biochemistry - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2002 - 2026
Source: PubMed

Institut Gustave Roussy

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1398

Citations

Citations: 50 906 1st author: 105 Last author: 329 Unique author: 3

Main journals

Ann Oncol 250
J Thorac Oncol 218
J Clin Oncol 162
Cancer Res 72
Eur J Cancer 63

Best Journals

Ann Oncol 134
J Clin Oncol 77
Lancet Oncol 13

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry.
PMID 42873584 — registries, pemetrexed, lung, neoplasms, immunotherapy, lung neoplasms, therapeutics		Clin Cancer Res20260
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.
PMID 42697029 — cells, lung, disease-free survival, progression-free survival, neoplasms, carcinoma, non-small-cell lung, drug therapy, biomarkers, lung neoplasms, small cell lung carcinoma, therapeutics, chemotherapy		Clin Lung Cancer20260
Impact of immunotherapy on overall survival and healthcare costs in advanced/metastatic lung cancer: A real-world study in France.
PMID 42497525 — health care costs, lung, neoplasms, immunotherapy, lung neoplasms, therapeutics		Lung Cancer20260
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
PMID 42532338 — research design, neoplasms, carcinoma, non-small-cell lung, uncertainty, therapeutics, rna		J Thorac Oncol20261
Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials.
PMID 42520592 — cells, lung, neoplasms, drug therapy, biomarkers, immunotherapy, lung neoplasms, small cell lung carcinoma, therapeutics, chemotherapy		Eur J Cancer20260

Clinical Studies 62

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7

By phase:

Phase 3 18
Phase 2 17
N/A 10
Phase 1/Phase 2 8
Phase 1 7
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 30
Active not recruiting 13
Recruiting 10
Terminated 4
Unknown 4
Not yet recruiting 1

By type:

Interventional 58
Observational 4

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 5
multicentric5to9 3
multicentricup10 45

Main Topics

Ongoing Clinical Trials

12 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non Small Cell Lung Cancer (NSCLC) after immunotherapy failure
2023-509340-10-00 — cells, lung, safety, vaccines, docetaxel, neoplasms, phenotype, carcinoma, non-small-cell lung, drug therapy, immunotherapy, immune checkpoint inhibitors, lung neoplasms, small cell lung carcinoma, hla-a2 antigen, therapeutics, cancer vaccines, chemotherapy		Phase 3Recruiting2024
Maintenance Pembrolizumab at Usual or Low doSE in non squamous lung cancer a non inferiority study
2023-503481-23-00 — lung, neoplasms, maintenance, lung neoplasms		Phase 3Recruiting2023
PRedictive Value of Multiparametric Dynamic WB 18F FDG PET Imaging on a LAFOV System for FIRST line Chemo immunotherapy Efficacy in Advanced Non small cell Lung Cancer PROFIL 1
NCT06738680 — cells, lung, positron-emission tomography, neoplasms, carcinoma, non-small-cell lung, predictive value of tests, biomarkers, immunotherapy, fluorodeoxyglucose f18, lung neoplasms, small cell lung carcinoma, therapeutics, carcinoma		N/ANot yet recruiting2025
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non small Cell Lung Cancer Tumors)
NCT05973773 — cells, epidermal growth factor, lung, growth, safety, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, tablets, drug therapy, exons, lung neoplasms, receptors, growth factor, small cell lung carcinoma, lung diseases, mutation, chemotherapy, carcinoma		Phase 3Active not recruiting2023
Maintenance Pembrolizumab at Usual or Low doSE in Non squamous Lung Cancer a Non inferiority Study
NCT05692999 — cells, pemetrexed, lung, absenteeism, neoplasms, carcinoma, non-small-cell lung, maintenance, lung neoplasms, therapeutics, carcinoma		Phase 3Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS